PE20160682A1 - Composiciones y metodos para modular los receptores x farnesoides - Google Patents
Composiciones y metodos para modular los receptores x farnesoidesInfo
- Publication number
- PE20160682A1 PE20160682A1 PE2016000596A PE2016000596A PE20160682A1 PE 20160682 A1 PE20160682 A1 PE 20160682A1 PE 2016000596 A PE2016000596 A PE 2016000596A PE 2016000596 A PE2016000596 A PE 2016000596A PE 20160682 A1 PE20160682 A1 PE 20160682A1
- Authority
- PE
- Peru
- Prior art keywords
- receptors
- modulate
- pharnesoid
- compositions
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical compound NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 abstract 1
- 239000005711 Benzoic acid Substances 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 235000010233 benzoic acid Nutrition 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900013P | 2013-11-05 | 2013-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160682A1 true PE20160682A1 (es) | 2016-07-23 |
Family
ID=51982773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000596A PE20160682A1 (es) | 2013-11-05 | 2014-11-04 | Composiciones y metodos para modular los receptores x farnesoides |
Country Status (42)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| SG11201603026PA (en) | 2013-11-05 | 2016-05-30 | Novartis Ag | Compositions and methods for modulating farnesoid x receptors |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| US10351576B2 (en) | 2015-04-30 | 2019-07-16 | Novartis Ag | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors |
| LT3419625T (lt) | 2016-02-22 | 2021-07-26 | Novartis Ag | Fxr agonistų panaudojimo būdai |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| JP6915050B2 (ja) * | 2016-09-14 | 2021-08-04 | ノバルティス アーゲー | Ｆｘｒアゴニストの新規のレジーム |
| PE20190972A1 (es) * | 2016-09-14 | 2019-07-09 | Novartis Ag | Combinacion de agonistas de fxr |
| MX2019003889A (es) * | 2016-10-05 | 2019-08-12 | Novartis Ag | Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico. |
| CN107973790A (zh) * | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| ES2982801T3 (es) | 2017-03-28 | 2024-10-17 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas |
| WO2018226155A1 (en) * | 2017-06-05 | 2018-12-13 | National University Of Singapore | Compounds useful in inhibiting human trefoil factor 3 |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| JP2020533339A (ja) * | 2017-09-13 | 2020-11-19 | ノバルティス アーゲー | Ｆｘｒアゴニストを含む組合せ |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| CN110128432B (zh) * | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| KR102692309B1 (ko) | 2019-01-15 | 2024-08-07 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
| US10610280B1 (en) | 2019-02-02 | 2020-04-07 | Ayad K. M. Agha | Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat |
| WO2020172075A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| TW202122078A (zh) | 2019-09-06 | 2021-06-16 | 瑞士商諾華公司 | 使用lta4h抑制劑治療肝臟疾病之方法 |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists for treating an infection by hepatitis d virus |
| CN113387828A (zh) * | 2020-03-14 | 2021-09-14 | 江巨东 | 一种阿利克仑中间体的制备方法 |
| WO2022037663A1 (zh) * | 2020-08-21 | 2022-02-24 | 苏州晶云药物科技股份有限公司 | 苯甲酸衍生物的新晶型及其制备方法 |
| MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
| TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| EP4577206A2 (en) * | 2022-08-26 | 2025-07-02 | Celmatix Inc. | Novel modulators of fshr and uses thereof |
| WO2026133229A1 (en) | 2024-12-20 | 2026-06-25 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050143449A1 (en) * | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| DK2029547T3 (da) * | 2006-05-24 | 2010-07-26 | Lilly Co Eli | FXR-agonister |
| JP2010504032A (ja) * | 2006-09-15 | 2010-02-04 | タレス アビオニクス インコーポレイテッド | 航空機との間でコンテンツを無線で転送するシステム及び方法 |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| SG11201603026PA (en) | 2013-11-05 | 2016-05-30 | Novartis Ag | Compositions and methods for modulating farnesoid x receptors |
| US10351576B2 (en) | 2015-04-30 | 2019-07-16 | Novartis Ag | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors |
-
2014
- 2014-11-04 SG SG11201603026PA patent/SG11201603026PA/en unknown
- 2014-11-04 BR BR112016009630-4A patent/BR112016009630B1/pt not_active IP Right Cessation
- 2014-11-04 WO PCT/US2014/063948 patent/WO2015069666A1/en not_active Ceased
- 2014-11-04 CN CN201480058975.8A patent/CN105682656B/zh not_active Expired - Fee Related
- 2014-11-04 SI SI201430692T patent/SI3065738T1/en unknown
- 2014-11-04 PE PE2016000596A patent/PE20160682A1/es unknown
- 2014-11-04 RS RS20180524A patent/RS57179B1/sr unknown
- 2014-11-04 MX MX2016005865A patent/MX364834B/es active IP Right Grant
- 2014-11-04 ES ES14803001.8T patent/ES2670984T3/es active Active
- 2014-11-04 AP AP2016009165A patent/AP2016009165A0/en unknown
- 2014-11-04 TN TN2016000143A patent/TN2016000143A1/en unknown
- 2014-11-04 NZ NZ719078A patent/NZ719078A/en not_active IP Right Cessation
- 2014-11-04 AU AU2014346919A patent/AU2014346919B2/en not_active Ceased
- 2014-11-04 CU CU2016000063A patent/CU24375B1/es unknown
- 2014-11-04 TW TW103138253A patent/TWI662027B/zh not_active IP Right Cessation
- 2014-11-04 PT PT148030018T patent/PT3065738T/pt unknown
- 2014-11-04 US US15/034,280 patent/US9682939B2/en active Active
- 2014-11-04 EA EA201690930A patent/EA030430B1/ru not_active IP Right Cessation
- 2014-11-04 MY MYPI2016701351A patent/MY175903A/en unknown
- 2014-11-04 PL PL14803001T patent/PL3065738T3/pl unknown
- 2014-11-04 TR TR2018/07321T patent/TR201807321T4/tr unknown
- 2014-11-04 UY UY0001035818A patent/UY35818A/es not_active Application Discontinuation
- 2014-11-04 DK DK14803001.8T patent/DK3065738T3/en active
- 2014-11-04 MA MA39088A patent/MA39088B1/fr unknown
- 2014-11-04 KR KR1020167014613A patent/KR102350357B1/ko not_active Expired - Fee Related
- 2014-11-04 HR HRP20180817TT patent/HRP20180817T1/hr unknown
- 2014-11-04 EP EP14803001.8A patent/EP3065738B1/en active Active
- 2014-11-04 HU HUE14803001A patent/HUE039155T2/hu unknown
- 2014-11-04 LT LTEP14803001.8T patent/LT3065738T/lt unknown
- 2014-11-04 JP JP2016552453A patent/JP6424231B2/ja not_active Expired - Fee Related
- 2014-11-04 CA CA2927705A patent/CA2927705C/en not_active Expired - Fee Related
- 2014-11-05 JO JOP/2014/0318A patent/JO3454B1/ar active
- 2014-11-05 AR ARP140104163A patent/AR098316A1/es unknown
-
2015
- 2015-03-17 NO NO15712554A patent/NO3105103T3/no unknown
-
2016
- 2016-04-14 ZA ZA2016/02555A patent/ZA201602555B/en unknown
- 2016-04-20 IL IL245242A patent/IL245242B/en active IP Right Grant
- 2016-04-25 CL CL2016000982A patent/CL2016000982A1/es unknown
- 2016-04-26 PH PH12016500777A patent/PH12016500777B1/en unknown
- 2016-05-05 SV SV2016005192A patent/SV2016005192A/es unknown
- 2016-05-05 GT GT201600085A patent/GT201600085A/es unknown
- 2016-05-05 CR CR20160212A patent/CR20160212A/es unknown
-
2017
- 2017-05-18 US US15/598,734 patent/US10077240B2/en active Active
-
2018
- 2018-05-24 CY CY20181100557T patent/CY1120273T1/el unknown
- 2018-08-07 US US16/056,881 patent/US10683271B2/en active Active
-
2020
- 2020-04-21 US US16/854,762 patent/US11021446B2/en not_active Expired - Fee Related
-
2021
- 2021-04-21 US US17/236,596 patent/US20210253534A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| EA201100944A1 (ru) | Производные изоксазола, предназначенные для применения в качестве регуляторов роста растений | |
| PE20191495A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| CO6680699A2 (es) | Derivados de amina para el control de plagas | |
| CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| PE20160548A1 (es) | Sulfonamidas como moduladores de canales de sodio | |
| PH12016501829B1 (en) | Plant disease control composition and method for controlling plant disease by application of same | |
| PE20142294A1 (es) | Compuestos de indol e indazol que activan la ampk | |
| AR072224A1 (es) | Derivados de pirimidona sustituidos | |
| MX359882B (es) | Amidas como moduladores de canales de sodio. | |
| PY1923494A (es) | Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida | |
| JP2016509589A5 (enExample) | ||
| AR098912A1 (es) | Inhibidores de syk | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| UA110647C2 (uk) | Похідне азолу, спосіб його одержання, проміжна сполука і хімічний агент, призначений для застосування в сільському господарстві і садівництві, і агент для захисту промислових матеріалів | |
| PE20090757A1 (es) | Formulaciones que contienen triazinonas y hierro | |
| JOP20200024A1 (ar) | مركبات ثنائي هيدروكساديازينون | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| UY35796A (es) | ?derivados de dihidrohidantoína sustituidos, procesos para prepararlos, composiciones herbicidas y su uso en plantas?. | |
| EA201492255A1 (ru) | Феноксиэтилпиперидиновые соединения | |
| MX2016015467A (es) | Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos. | |
| PE20081533A1 (es) | Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que contienen los mismos | |
| MY137761A (en) | The use of n-arylhdrazine derivatives for combating non-crop pests |